METHODS AND COMPOSITIONS TO TREAT MYOCARDIAL CONDITIONS

• US 20080208167A1
• Filed: 05/02/2008
• Published: 08/28/2008
• Est. Priority Date: 04/15/2003
• Status: Abandoned Application

• Current Assignee: Eugene T. Michal, John C. Stankus
• Original Assignee: Eugene T. Michal, John C. Stankus
• Inventors: Michal, Eugene T., Stankus, John
• Application Number:
  US12/114,717
• Publication Number:
  US 20080208167A1
• Time in Patent Office: Days
• US Class Current: 604/511
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/728 Hyaluronic acid
• CPC Class Codes: A61K 31/732 Pectin
• CPC Class Codes: A61K 31/734 Alginic acid
• CPC Class Codes: A61K 31/78 of acrylic acid or derivatives thereof
• CPC Class Codes: A61K 31/79 Polymers of vinyl pyrrolidone
• CPC Class Codes: A61K 35/34 Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes vascular smooth muscle A61K35/44
• CPC Class Codes: A61K 36/886 Aloeaceae (Aloe family), e.g. aloe vera
• CPC Class Codes: A61K 38/18 Growth factors; Growth regulators
• CPC Class Codes: A61K 38/1825 Fibroblast growth factor [FGF]
• CPC Class Codes: A61K 38/1841 Transforming growth factor [TGF]
• CPC Class Codes: A61K 38/1858 Platelet-derived growth factor [PDGF]
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 38/1891 Angiogenesic factors; Angiogenin
• CPC Class Codes: A61K 38/40 Transferrins, e.g. lactoferrins, ovotransferrins
• CPC Class Codes: A61K 41/0042 Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/62 : the modifying agent being a protein, peptide or polyamino acid
• CPC Class Codes: A61K 49/0404 : containing barium sulfate
• CPC Class Codes: A61K 9/0024 : Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 24/043 : Mixtures of macromolecular materials
• CPC Class Codes: A61L 2430/20 : for reconstruction of the heart, e.g. heart valves
• CPC Class Codes: A61L 27/20 : Polysaccharides
• CPC Class Codes: A61L 27/50 : Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 27/54 : Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61N 1/3625 : External stimulators
• CPC Class Codes: A61N 1/36521 : the parameter being derived from measurement of an electrical impedance
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 7/04 : Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
• CPC Class Codes: A61P 9/04 : Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61P 9/14 : Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Methods, devices, kits and compositions to treat a myocardial infarction. In one embodiment, the method includes the prevention of remodeling of the infarct zone of the ventricle. In other embodiments, the method includes the introduction of structural reinforcing agents such as those agents containing aloe-derived pectin. In other embodiments, the structural reinforcing agent may be accompanied by other therapeutic agents. These agents may include, but are not, limited to pro-fibroblastic and angiogenic agents.

Claims

1. A method comprising identifying an infarct region within the ventricle of a subject;

and

delivering near or in the infarct region material comprising aloe-derived pectin.

3. The method of claim 1 wherein delivering aloe-derived pectin prevents thinning of the ventricle.

4. The method of claim 1 wherein delivery of the aloe-derived pectin occurs within 2 weeks of a myocardial infarction (MI).

5. The method of claim 1 wherein delivery of the aloe-derived pectin occurs within 5, 10, 15, or 20 weeks of a myocardial infarction (MI).

6. The method of claim 1 wherein the aloe-derived pectin material further comprises at least one of cells, proteins, peptides, growth factors or microparticles containing at least one of cells, proteins, peptides, or growth factors or nanoparticles containing at least one of cells, proteins, peptides or growth factors.

7. The method of claim 6 wherein the aloe-derived pectin material comprises cells and proteins, cells and growth factors, or proteins and growth factors.

8. The method of claim 1 wherein said subject with the MI displays at least 20 percent ventricular damage.

9. The method of claim 1 wherein the aloe-derived pectin displays a pseudoplastic characteristic.

10. The method of claim 1 wherein delivering aloe-derived pectin comprises:

delivering the aloe-derived pectin material to the infarct region in a liquid phase and once delivered the aloe-derived pectin material is capable of transitioning to a solid phase in the presence of an endogenous material.

11. The method of claim 1 further comprising delivering at least one matrix metalloproteinase inhibitor (MMPIs) to the ventricle.

12. The method of claim 1 wherein delivering the aloe-derived pectin comprises introducing the aloe-derived pectin to the ventricle through a procedure.

13. The method of claim 12 wherein the procedure to the ventricle region is selected from at least one of minimally invasive such as sub-xiphoid, percutaneous, or surgical approach such as open-chest procedure in conjunction with Coronary Bypass Graft (CABG).

14. The method of claim 13 wherein the percutaneous introduction of the aloe-derived pectin into the ventricle comprises at least one of the following modes consisting of intracoronary infusion, intraventricular catheter, intravenous pressure perfusion, transvascular needle catheter, and retrograde venous perfusion.

15. The method of claim 1 wherein delivering the aloe-derived pectin comprises delivering a composition suspended in a solution.

16. The method of claim 1 wherein delivering aloe-derived pectin near the infarct region is capable of increasing the compliance of the ventricle.

2. A method comprising identifying an infarct region within the ventricle of a subject;

and

delivering to the infarct region material comprising aloe-derived pectin.

17. A kit comprising a delivery lumen;

agents delivered from the delivery lumen; and

at least one agent comprising a structural reinforcing agent wherein said structural reinforcing agent is capable of forming a matrix product within a ventricle wherein the structural re-inforcing agent comprises a material comprising aloe-derived pectin.

18. The kit of claim 17 further comprising forming a matrix product within or near an infarct region of a ventricle.

19. The kit of 17 further comprising a delivery device.

20. The kit of 17 wherein the structural reinforcing agent comprises a material in a liquid phase and once delivered the material is capable of transitioning to a solid phase in the presence of an endogenous material in or near an infarct region.

21. A kit comprising a delivery lumen and agents comprising aloe-derived pectin, wherein the agents are capable of increasing the compliance of a ventricle.

22. The kit of claim 21 further comprising a delivery device.

23. A method comprising delivering a liquid phase of a structural reinforcing agent to a ventricle wherein the structural reinforcing agent is capable of transitioning to a solid when an environmental temperature is approximately a body temperature of a mammalian subject and wherein the structural reinforcing agent comprises a material comprising aloe-derived pectin.

24. The method of claim 23 wherein delivering a liquid phase of a structural reinforcing agent to a ventricle comprises delivering a liquid phase of a structural reinforcing agent to or near an infarct region of a ventricle.

25. A method comprising delivering a first material and a second different material to a ventricle wherein a first material and a second different material are components of a final product and wherein the first or second material comprises aloe-derived pectin.

26. The method of claim 25 wherein the final product prevents thinning of the ventricle.

27. A kit comprising at least two delivery lumen;

agents delivered from each delivery lumen; and

a first material and a second different material wherein the first material and the second different material are components of a final product and are capable of forming the final product within a ventricle and wherein the first or second material comprises aloe-derived pectin.

28. The kit of claim 27 wherein the first material and the second material are housed in separate lumen.

29. The kit of claim 27 wherein a final product is formed within or near an infarct region of a ventricle from the first material and the second material.

30. The kit of claim 27 further comprising a delivery device.

31. The kit of claim 30 wherein the delivery device comprises a dual chamber delivery device comprising separate chambers for the first material and the second different material.